We next detected CD133+ cancer cells remaining in tumor tissues by IHC staining of CD133 in the tumor samples collected 15 days after treatment and showed that the majority of residual tumor cells were CD133-negative, but there were also residual CD133-positive tumor cells (Supplementary Figure S9C). This evidence concerns the gene PROM1 and neoplasm.